Launch of Novel Targeted Therapies Provides Significant Boost to Non-Small Cell Lung Cancer (NSCLC) Market in 8MM

Published Date : Mar 14, 2017

Albany, New York, March 14, 2017: has announced the inclusion of a report, titled “PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast And Market Analysis To 2025,”to its database. The report is a professional study of the NSCLC market, which provides insights into the sales of NSCLC-specific drug in 8MM countries, which are the U.S., Germany, France, Spain, Italy, and the U.K., China, and Japan. As per the findings of the report, the market in 8MM was valued at US$6.2 bn in 2015 and is estimated to reach US$26.71 bn by 2025, posting an impressive CAGR of 15.7% therein. The current market is witnessing high sales of anti-angiogenic agents, major chemotherapy regimens, and targeted therapies for patients with ALK+ and EGFR+ NSCLC.
In present scenario, lung cancer is the leading cause of death from cancer across the world. NSCLC is the most common type of lung cancer, accounting for about 85.0% of all the cases. NSCLC patients are generally diagnosed in the later stages of the disease, with seldom accurate prognosis, which makes the treatment difficult. 

For Sample Copy, click here: 

Until a few years ago, the treatment options were limited to chemotherapy. However, the advent of targeted therapies for patients with specific biomarkers has brought about a change in the NSCLC market by fragmenting the treatment landscape into smaller niche patient populations. Over the forthcoming years, this trend will continue with the birthing of several novel drugs in various new drug classes to attend to the high unmet needs of NSCLC patients, and offer new treatment routes for previously underserved populations. However, the launch of targeted therapies, including Tarceva (erlotinib), Iressa (gefitinib), and Xalkori (crizotinib), has caused a paradigm shift towards personalized medicine in the treatment landscape.

The increasing prevalence of NSCLC in the 8MM countries is by far the leading factor augmenting the the NSCLC market. The growing geriatric population in these countries is contributing to the high occurrence of the disease. Across the 8MM, the prevalence of NSCLC is likely to progress at CAGR of 3.1% during the review period. China, in particular, is poised to experience dramatic rise in the number of cases over the same period, at a CAGR of 4.7%. 

Moreover, the increasing integration of premium-priced immunotherapies with the NSCLC treatment algorithm, especially in the first-line setting, is providing a fillip to the market. Immunotherapies are estimated to register sales worth US$17.5 bn by 2025, representing nearly 65.0% of total sales in the NSCLC market. Of these, branded immunotherapies such as Opdivo, Keytruda, and Tecentriq are projected to contribute US$5.5 bn, US$5.2 bn, and US$2.8B, respectively. However, the patent expiration of several blockbuster drugs and the high cost of therapeutics along with the lack of reimbursement policies are hampering the growth of the market. 

To order report Call Toll Free: 866-997-4948 or send an email on